臨床試験アウトソーシング市場 - 世界の見通しと予測（2022年～2027年）

世界の臨床試験アウトソーシングの市場規模は、予測期間の2022年～2027年に6.71%のCAGRで拡大すると予測されています。

当レポートでは、世界の臨床試験アウトソーシング市場について調査し、市場の概要とともに、相別、用途別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 調査手法

第2章 調査目的

第3章 調査プロセス

第4章 範囲と適用範囲

第5章 レポートの前提と注意事項

第6章 市場概要

第7章 イントロダクション

• 概要

第8章 重要考察

第9章 市場機会と動向

第10章 市場の促進要因

第11章 市場の抑制要因

第12章 市場情勢

• 市場概要
• 市場規模と予測
• ファイブフォース分析

第13章 相別市場

• 市場概要および成長促進要因
• 市場概要
• 第Ⅲ相
• 第Ⅱ相
• 第IV相
• 第I相

第14章 用途別市場

• 市場概要および成長促進要因
• 市場概要
• 癌
• 心血管疾患
• 神経系障害
• 感染症
• 筋骨格系疾患
• 消化器疾患
• その他

第15章 エンドユーザー別市場

• 市場概要および成長促進要因
• 市場概要
• 中小企業
• 大企業

第16章 地域別市場

第17章 北米

第18章 欧州

第19章 アジア太平洋

第20章 ラテンアメリカ

第21章 中東・アフリカ

第22章 競合情勢

第23章 主要な企業プロファイル

• CHARLES RIVER LABORATORIES
• IQVIA
• ICON PLC
• LABCORP DRUG DEVELOPMENT
• SYNEOS HEALTH
• THERMO FISHER SCIENTIFIC
• WUXI APPTEC
• PARAXEL

第24章 その他の著名なベンダー

• ADVANCED CLINICAL
• BIOANALYTIX
• CURIA GLOBAL
• CMED
• CROMOS PHARMA
• CRITERIUM
• KCR S.A
• MEDPACE
• MEDELIS
• OCT GROUP
• PROTRIALS RESEARCH
• PROMETRIKA
• QUALITY DATA SERVICES
• QPS
• SOFPROMED
• VERISTAT
• WORLDWIDE CLINICAL TRIALS

第25章 レポートの概要

第26章 定量的要約

第27章 付録

LIST OF EXHIBITS

• EXHIBIT 1 SEGMENTATION OF GLOBAL CLINICAL TRIALS OUTSOURCING MARKET
• EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
• EXHIBIT 3 TOTAL NUMBER OF CLINICAL TRIALS 2000-2020
• EXHIBIT 4 CLINICAL TRIALS CONDUCTED BY COUNTRIES UNTIL 2022
• EXHIBIT 5 GROWTH DRIVERS FOR CLINICAL TRIAL OUTSOURCING MARKET
• EXHIBIT 6 CLINICAL TRIAL BY PHASE OF DEVELOPMENT 1999-2021
• EXHIBIT 7 TOTAL NUMBER OF CLINICAL TRIALS BY PHASES 2022
• EXHIBIT 8 CLINICAL TRIALS & PRE-FORMULATION CORRELATION
• EXHIBIT 9 FACTORS DRIVING CLINICAL TRIAL OUTSOURCING
• EXHIBIT 10 ESTIMATED NUMBER OF CLINICAL TRIALS REGISTERED 2000-2023
• EXHIBIT 11 IMPACT OF RISING DEMAND FOR PATIENT-CENTRIC & DECENTRALIZED CLINICAL TRIALS
• EXHIBIT 12 ADVANTAGES OF VIRTUAL CLINICAL TRIALS
• EXHIBIT 13 IMPACT OF REVOLUTIONIZING EFFECTS OF AI ON CLINICAL TRIALS
• EXHIBIT 14 BENEFITS OF AI IN CLINICAL TRIALS
• EXHIBIT 15 IMPACT OF ENTRY OF START-UPS SPECIALIZING IN DRUG DISCOVERY
• EXHIBIT 16 NEW DRUG APPROVALS BY DIFFERENT TYPES OF PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 2009-2018
• EXHIBIT 17 IMPACT OF INCREASING ADOPTION OF SYNTHETIC CLINICAL TRIALS
• EXHIBIT 18 IMPACT OF SURGE IN DRUG DISCOVERY INITIATIVES & ASSOCIATED EXPENDITURE
• EXHIBIT 19 INCREASING EXPENDITURE & RISING DRUG DISCOVERY PROGRAMMES 2000-2021
• EXHIBIT 20 NUMBER OF REGISTERED CLINICAL STUDIES 2000-2023
• EXHIBIT 21 TOP PHARMACEUTICAL COMPANIES RANKED BY R&D SPENDING (% OF REVENUE)
• EXHIBIT 22 DRUGS IN DEVELOPMENT BY THERAPEUTIC AREAS
• EXHIBIT 23 IMPACT OF HIGH DEMAND FOR LARGE MOLECULE PRODUCTS & PERSONALIZED MEDICINES
• EXHIBIT 24 CLASSIFICATION OF LARGE MOLECULES
• EXHIBIT 25 NOVEL NEW DRUGS & BIOLOGICS DRUGS APPROVED BY FDA FOR RARE DISEASES UNTIL 2021
• EXHIBIT 26 IMPACT OF INITIATIVES TO IMPROVE EFFICIENCY IN CLINICAL TRIALS
• EXHIBIT 27 IMPACT OF RISE IN STRATEGIC PARTNERSHIPS AND R&D COLLABORATIONS
• EXHIBIT 28 KEY THEMES FOR OPTIMIZING COLLABORATION EFFECTIVENESS
• EXHIBIT 29 IMPACT OF GEOGRAPHICAL LOCATIONS & CRUCIAL REGULATORY ASPECTS FOR CLINICAL TRIALS
• EXHIBIT 30 CHALLENGES IN CLINICAL RESEARCH AND CLINICAL TRIALS
• EXHIBIT 31 IMPACT OF LONG TIMELINES AND LACK OF TRANSPARENCY & SPECIFICITY
• EXHIBIT 32 IMPACT OF INCREASING COMPLEXITY OF CLINICAL TRIALS
• EXHIBIT 33 FACTORS RESPONSIBLE FOR INCREASE IN COMPLEXITY OF CLINICAL TRIALS
• EXHIBIT 34 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY: MARKET SHARE ANALYSIS 2021 & 2027
• EXHIBIT 35 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE: MARKET SHARE ANALYSIS 2021 & 2027
• EXHIBIT 36 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION: MARKET SHARE ANALYSIS 2021 & 2027
• EXHIBIT 37 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY END USER: MARKET SHARE ANALYSIS 2021 & 2027
• EXHIBIT 38 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 39 FIVE FORCES ANALYSIS 2021
• EXHIBIT 40 INCREMENTAL GROWTH BY PHASE 2021 & 2027
• EXHIBIT 41 GLOBAL PHASE III CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 42 CLINICAL TRIAL OUTSOURCING MARKET BY PHASE 2022-2027
• EXHIBIT 43 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE: OVERVIEW
• EXHIBIT 44 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE: INCREMENTAL GROWTH
• EXHIBIT 45 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE: ABSOLUTE GROWTH
• EXHIBIT 46 PROBABILITY OF PHASE III SUCCESS 2010-2020
• EXHIBIT 47 GLOBAL PHASE III CLINICAL TRIAL OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
• EXHIBIT 48 GLOBAL PHASE II CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
• EXHIBIT 49 GLOBAL PHASE II CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 50 GLOBAL PHASE IV CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
• EXHIBIT 51 PHASE IV: STUDIES CONDUCTED IN PHASE IV
• EXHIBIT 52 GLOBAL PHASE IV CLINICAL TRIAL OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 53 GLOBAL PHASE I CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 54 GLOBAL PHASE I CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
• EXHIBIT 55 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
• EXHIBIT 56 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2022-2027
• EXHIBIT 57 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION: OVERVIEW
• EXHIBIT 58 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION: INCREMENTAL GROWTH
• EXHIBIT 59 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION: ABSOLUTE GROWTH
• EXHIBIT 60 ONCOLOGY CLINICAL TRIALS BY PHASE 2020 (%).
• EXHIBIT 61 PERCENTAGE OF DRUG PIPELINES DEDICATED TO CANCER 2010-2019
• EXHIBIT 62 GLOBAL CANCER CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 63 GLOBAL CANCER CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
• EXHIBIT 64 CARDIOVASCULAR DISEASES: GROUP OF DISEASES OF BLOOD VESSELS AND HEART
• EXHIBIT 65 GLOBAL CARDIOVASCULAR DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 66 GLOBAL CARDIOVASCULAR DISEASES CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
• EXHIBIT 67 GLOBAL PREVALENCE OF NEUROLOGICAL DISORDERS 2019-2021
• EXHIBIT 68 GLOBAL NERVOUS SYSTEM DISORDERS CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 69 GLOBAL NERVOUS SYSTEM DISORDERS CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
• EXHIBIT 70 PATIENT POPULATION FOR INFECTIOUS DISEASES
• EXHIBIT 71 GLOBAL INFECTIOUS DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 72 GLOBAL INFECTIOUS DISEASES CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
• EXHIBIT 73 PREVALENCE OF MUSCULOSKELETAL CONDITIONS WORLDWIDE 2021
• EXHIBIT 74 PREVALENCE OF MUSCULOSKELETAL DISEASES BY CONDITION 2021
• EXHIBIT 75 GLOBAL MUSCULOSKELETAL DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 76 GLOBAL MUSCULOSKELETAL DISEASES CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
• EXHIBIT 77 GLOBAL GASTROENTEROLOGY DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 78 GLOBAL GASTROENTEROLOGY DISEASES CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
• EXHIBIT 79 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY OTHER DISEASES: INCREMENT GROWTH & ABSOLUTE GROWTH
• EXHIBIT 80 GLOBAL OTHER DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 81 INCREMENTAL GROWTH BY END USER 2021 & 2027
• EXHIBIT 82 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2022-2027
• EXHIBIT 83 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY END-USER: OVERVIEW
• EXHIBIT 84 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY END-USER: GROWTH POTENTIAL
• EXHIBIT 85 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY END USER: INCREMENTAL GROWTH
• EXHIBIT 86 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY END USER: ABSOLUTE GROWTH
• EXHIBIT 87 NUMBER OF SMALL PHARMACEUTICAL/ BIOTECHNOLOGY COMPANIES WITH ACTIVE PIPELINES 2010-2019
• EXHIBIT 88 DRIVERS FOR CLINICAL TRIAL OUTSOURCING BY SMALL- & MID-SIZE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
• EXHIBIT 89 SMALL PHARMACEUTICAL/BIOTECHNOLOGY COMPANIES CONTRIBUTION TO NEW DRUG APPROVAL BY FDA 2020
• EXHIBIT 90 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY SMALL & MID SIZE ENTERPRISES 2021-2027 ($ BILLION)
• EXHIBIT 91 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY SMALL & MID SIZE ENTERPRISES: INCREMENT GROWTH & ABSOLUTE GROWTH
• EXHIBIT 92 TOP PHARMA COMPANIES WITH HIGH R&D EXPENDITURE 2021 (CHANGE FROM 2020-%) BILLION
• EXHIBIT 93 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY LARGE ENTERPRISES: INCREMENT GROWTH & ABSOLUTE GROWTH
• EXHIBIT 94 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY LARGE ENTERPRISES 2021-2027 ($ BILLION)
• EXHIBIT 95 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
• EXHIBIT 96 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY 2022-2027
• EXHIBIT 97 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY: INCREMENTAL GROWTH
• EXHIBIT 98 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY: ABSOLUTE GROWTH
• EXHIBIT 99 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET 2000-2021
• EXHIBIT 100 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET: KEY COUNTRIES
• EXHIBIT 101 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 102 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
• EXHIBIT 103 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027
• EXHIBIT 104 PERCENTAGE OF REGISTERED CLINICAL STUDIES BY LOCATION APRIL 2022 (TOTAL 410,703)
• EXHIBIT 105 CLINICAL TRIALS IN DIFFERENT THERAPEUTIC AREAS ACROSS US 2019
• EXHIBIT 106 US CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 107 CANADA: WORLD LEADING DESTINATION FOR CLINICAL TRIALS
• EXHIBIT 108 CANADA CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 109 EUROPE CLINICAL TRIALS OUTSOURCING MARKET: KEY COUNTRIES
• EXHIBIT 110 EUROPE CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 111 EUROPE CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
• EXHIBIT 112 INCREMENTAL GROWTH IN EUROPE 2021 & 2027
• EXHIBIT 113 INDUSTRY-SPONSORED CLINICAL TRIALS IN GERMANY 2011-2020 (%)
• EXHIBIT 114 INDUSTRY-SPONSORED CLINICAL TRIALS FOR DIFFERENT THERAPEUTIC AREAS IN GERMANY 2020 (%)
• EXHIBIT 115 GERMANY CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 116 CLINICAL TRIALS FUNDING & SOURCES IN UK
• EXHIBIT 117 UK CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 118 TOP THERAPY AREAS OF INDUSTRY-SPONSORED CLINICAL TRIALS IN FRANCE 2020 (%)
• EXHIBIT 119 FRANCE CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 120 SPAIN CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 121 TOP THERAPY AREAS FOR INDUSTRY-SPONSORED CLINICAL TRIALS IN ITALY
• EXHIBIT 122 ITALY CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 123 APAC CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
• EXHIBIT 124 REASONS FOR APAC BEING PREFERRED DESTINATION FOR CLINICAL TRIALS OUTSOURCING
• EXHIBIT 125 APAC CLINICAL TRIAL OUTSOURCING MARKET: KEY COUNTRIES
• EXHIBIT 126 APAC CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 127 INCREMENTAL GROWTH IN APAC 2021 & 2027
• EXHIBIT 128 CHINA: FACTORS INFLUENCING CLINICAL TRIAL OUTSOURCING MARKET GROWTH
• EXHIBIT 129 CHINA: CLINICAL TRIALS 2012-2021 (TEN YEAR TREND)
• EXHIBIT 130 CHINA CLINICAL TRIAL OUTSOURCING DRIVERS
• EXHIBIT 131 CHINA CLINICAL TRIAL OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 132 JAPAN CLINICAL TRIAL OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 133 FACTORS TRIGGERING CLINICAL TRIAL OUTSOURCING IN INDIA
• EXHIBIT 134 INDIA: CLINICAL TRIALS TEN YEAR TREND 2011-2020 (%)
• EXHIBIT 135 INDIA CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 136 AUSTRALIA CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 137 SOUTH KOREA: FACTOR INFLUENCING OUTSOURCING CLINICAL TRIALS DEMAND
• EXHIBIT 138 SOUTH KOREA CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 139 LATIN AMERICA CLINICAL TRIALS OUTSOURCING MARKET: KEY COUNTRIES
• EXHIBIT 140 LATIN AMERICA CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 141 LATIN AMERICA CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
• EXHIBIT 142 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027
• EXHIBIT 143 BRAZIL CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 144 MEXICO CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 145 MIDDLE EAST & AFRICA CLINICAL TRIALS OUTSOURCING MARKET: KEY COUNTRIES
• EXHIBIT 146 MIDDLE EAST & AFRICA CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 147 MIDDLE EAST & AFRICA CLINICAL TRIALS OUTSOURCING MARKET: INCREMENT GROWTH & ABSOLUTE GROWTH
• EXHIBIT 148 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2021 & 2027
• EXHIBIT 149 DRIVERS FOR TURKEY CLINICAL TRIAL OUTSOURCING MARKET
• EXHIBIT 150 TURKEY CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 151 NUMBER OF CLINICAL TRIALS IN EGYPT 2008-2017
• EXHIBIT 152 EGYPT CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 153 NUMBER OF CLINICAL TRIALS IN EGYPT PER YEAR
• EXHIBIT 154 SOUTH AFRICA CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 155 SAUDI ARABIA CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• EXHIBIT 156 PURE & DIVERSIFIED VENDORS IN GLOBAL CLINICAL TRIALS OUTSOURCING MARKET
• EXHIBIT 157 VENDORS OFFERING CLINICAL TRIALS OUTSOURCING: MARKET DOMINANCE ANALYSIS
• EXHIBIT 158 VENDORS OFFERING CLINICAL TRIALS OUTSOURCING: CAPABILITIES & EXPERTISE ASSESSMENT
• EXHIBIT 159 CHARLES RIVER LABORATORIES: REVENUE BY BUSINESS SEGMENT 2021
• EXHIBIT 160 CHARLES RIVER LABORATORIES: REVENUE BY CLIENT SEGMENT 2021
• EXHIBIT 161 CHARLES RIVER LABORATORIES: REVENUE BY GEOGRAPHY
• EXHIBIT 162 CHARLES RIVER LABORATORIES: ANNUAL REVENUE 2019-2021 ($ MILLION)
• EXHIBIT 163 IQVIA: REVENUE 2019-2021 ($ MILLION).
• EXHIBIT 164 IQVIA: R&D EXPENDITURE 2019-2021 ($ MILLION)
• EXHIBIT 165 ICON PLC: ANNUAL REVENUE 2019-2021 ($ MILLION)
• EXHIBIT 166 LABCORP DRUG DEVELOPMENT: REVENUE 2019-2021 (MILLION)
• EXHIBIT 167 SYNEOS HEALTH: REVENUE 2019-2021 ($ BILLION)
• EXHIBIT 168 THERMO FISHER SCIENTIFIC: REVENUE 2019-2021 ($ MILLION)
• EXHIBIT 169 THERMO FISHER SCIENTIFIC: REVENUE BY LABORATORY PRODUCTS & BIOPHARMA SERVICES SEGMENT 2019- 2021 ($ MILLION)
• EXHIBIT 170 THERMO FISHER SCIENTIFIC: TOTAL REVENUE BY GEOGRAPHIES 2019-2021 ($ MILLION)
• EXHIBIT 171 WUXI APPTEC: REVENUE 2019-2021 ($ BILLION)
• EXHIBIT 172 WUXI APPTEC: REVENUE BY GEOGRAPHY (%) 2021

LIST OF TABLES

• TABLE 1 KEY CAVEATS
• TABLE 2 CURRENCY CONVERSION 2015-2021
• TABLE 3 GLOBAL PHASE III CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION) (GEOGRAPHY)
• TABLE 4 GLOBAL PHASE III CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 (%) (GEOGRAPHY)
• TABLE 5 GLOBAL PHASE II CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION) (GEOGRAPHY)
• TABLE 6 GLOBAL PHASE II CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 (%) (GEOGRAPHY)
• TABLE 7 GLOBAL PHASE IV CLINICAL TRIAL OUTSOURCING MARKET BY GEOGRAPHY 2021-2027 ($ BILLION)
• TABLE 8 GLOBAL PHASE IV CLINICAL TRIAL OUTSOURCING MARKET BY GEOGRAPHY 2021-2027 (%)
• TABLE 9 GLOBAL PHASE I CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY 2021-2027 ($ BILLION)
• TABLE 10 GLOBAL PHASE I CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY 2021-2027 (%)
• TABLE 11 GLOBAL CANCER CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY 2021-2027 ($ BILLION)
• TABLE 12 GLOBAL CANCER CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY 2021-2027 (%)
• TABLE 13 GLOBAL CARDIOVASCULAR DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION) (GEOGRAPHY)
• TABLE 14 GLOBAL CARDIOVASCULAR DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 (%) (GEOGRAPHY)
• TABLE 15 GLOBAL NERVOUS SYSTEM DISORDERS CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION) (GEOGRAPHY)
• TABLE 16 GLOBAL NERVOUS SYSTEM DISORDERS CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 (%) (GEOGRAPHY)
• TABLE 17 GLOBAL INFECTIOUS DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION) (GEOGRAPHY)
• TABLE 18 GLOBAL INFECTIOUS DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 (%) (GEOGRAPHY)
• TABLE 19 GLOBAL MUSCULOSKELETAL DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION) (GEOGRAPHY)
• TABLE 20 GLOBAL MUSCULOSKELETAL DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 (%) (GEOGRAPHY)
• TABLE 21 GLOBAL GASTROENTEROLOGY DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION)
• TABLE 22 GLOBAL GASTROENTEROLOGY DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 (%)
• TABLE 23 GLOBAL OTHER DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 ($ BILLION) (GEOGRAPHY)
• TABLE 24 GLOBAL OTHER DISEASES CLINICAL TRIALS OUTSOURCING MARKET 2021-2027 (%) (GEOGRAPHY)
• TABLE 25 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY SMALL & MID SIZE ENTERPRISES 2021-2027 ($ BILLION)
• TABLE 26 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY SMALL & MID SIZE ENTERPRISES 2021-2027 (%)
• TABLE 27 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY LARGE ENTERPRISES 2021-2027 ($ BILLION) (GEOGRAPHY)
• TABLE 28 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY LARGE ENTERPRISES 2021-2027 (%) (GEOGRAPHY)
• TABLE 29 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021-2027 ($ BILLION)
• TABLE 30 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021-2027 (%)
• TABLE 31 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021-2027 ($ BILLION)
• TABLE 32 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021-2027 (%)
• TABLE 33 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021-2027 ($ BILLION)
• TABLE 34 NORTH AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021-2027 (%)
• TABLE 35 EUROPE CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021-2027 ($ BILLION)
• TABLE 36 EUROPE CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021-2027 (%)
• TABLE 37 EUROPE CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021-2027 ($ BILLION)
• TABLE 38 EUROPE CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021-2027 (%)
• TABLE 39 EUROPE CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021-2027 ($ BILLION)
• TABLE 40 EUROPE CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021-2027 (%)
• TABLE 41 APAC CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021-2027 ($ BILLION)
• TABLE 42 APAC CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021-2027 (%)
• TABLE 43 APAC CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021-2027 ($ BILLION)
• TABLE 44 APAC CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021-2027 (%)
• TABLE 45 APAC CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021-2027 ($ BILLION)
• TABLE 46 APAC CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021-2027 (%)
• TABLE 47 LATIN AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021-2027 ($ BILLION)
• TABLE 48 LATIN AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021-2027 (%)
• TABLE 49 LATIN AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021-2027 ($ BILLION)
• TABLE 50 LATIN AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021-2027 (%)
• TABLE 51 LATIN AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021-2027 ($ BILLION)
• TABLE 52 LATIN AMERICA CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021-2027 (%)
• TABLE 53 MIDDLE EAST & AFRICA CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021-2027 ($ BILLION)
• TABLE 54 MIDDLE EAST & AFRICA CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021-2027 (%)
• TABLE 55 MIDDLE EAST & AFRICA CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021-2027 ($ BILLION)
• TABLE 56 MIDDLE EAST & AFRICA CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021-2027 (%)
• TABLE 57 MIDDLE EAST & AFRICA CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021-2027 ($ BILLION)
• TABLE 58 MIDDLE EAST & AFRICA CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021-2027 (%)
• TABLE 59 CHARLES RIVER LABORATORIES: MAJOR PRODUCT OFFERINGS
• TABLE 60 IQVIA: MAJOR PRODUCT OFFERINGS
• TABLE 61 ICON PLC: MAJOR PRODUCT OFFERINGS
• TABLE 62 LABCORP DRUG DEVELOPMENT: MAJOR SERVICE OFFERINGS
• TABLE 63 SYNEOS HEALTH: MAJOR SERVICE OFFERINGS
• TABLE 64 THERMO FISHER SCIENTIFIC: MAJOR SERVICE OFFERINGS
• TABLE 65 WUXI APPTEC: MAJOR SERVICE OFFERINGS
• TABLE 66 PARAXEL: MAJOR SERVICE OFFERINGS
• TABLE 67 ADVANCED CLINICAL: MAJOR SERVICE OFFERINGS
• TABLE 68 BIOANALYTIX: MAJOR SERVICE OFFERINGS
• TABLE 69 CURIA GLOBAL: MAJOR SERVICE OFFERINGS
• TABLE 70 CMED: MAJOR SERVICE OFFERINGS
• TABLE 71 CROMOS PHARMA: MAJOR SERVICE OFFERINGS
• TABLE 72 CRITERIUM: MAJOR SERVICE OFFERINGS
• TABLE 73 KCR S.A.: MAJOR SERVICE OFFERINGS
• TABLE 74 MEDPACE: MAJOR SERVICE OFFERINGS
• TABLE 75 MEDELIS: MAJOR SERVICE OFFERINGS
• TABLE 76 OCT GROUP: MAJOR SERVICE OFFERINGS
• TABLE 77 PROTRIALS RESEARCH: MAJOR SERVICE OFFERINGS
• TABLE 78 PROMETRIKA: MAJOR SERVICE OFFERINGS
• TABLE 79 QUALITY DATA SERVICES: MAJOR SERVICE OFFERINGS
• TABLE 80 QPS: MAJOR SERVICE OFFERINGS
• TABLE 81 SOFPROMED: MAJOR SERVICE OFFERINGS
• TABLE 82 VERISTAT: MAJOR SERVICE OFFERINGS
• TABLE 83 WORLDWIDE CLINICAL TRIALS: MAJOR SERVICE OFFERINGS
• TABLE 84 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY 2021-2027 ($ BILLION)
• TABLE 85 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY GEOGRAPHY 2021-2027 (%)
• TABLE 86 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021-2027 ($ BILLION)
• TABLE 87 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE 2021-2027 (%)
• TABLE 88 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021-2027 ($ BILLION)
• TABLE 89 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY APPLICATION 2021-2027 (%)
• TABLE 90 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021-2027 ($ BILLION)
• TABLE 91 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY END USER 2021-2027 (%)
• TABLE 92 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE III 2021-2027 ($ BILLION) (GEOGRAPHY)
• TABLE 93 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE III 2021-2027 (%) (GEOGRAPHY)
• TABLE 94 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE II 2021-2027 (%) (GEOGRAPHY)
• TABLE 95 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE II 2021-2027 (%) (GEOGRAPHY)
• TABLE 96 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE IV 2021-2027 (%) (GEOGRAPHY)
• TABLE 97 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE IV 2021-2027 (%) (GEOGRAPHY)
• TABLE 98 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE I 2021-2027 (%) (GEOGRAPHY)
• TABLE 99 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY PHASE I 2021-2027 (%) (GEOGRAPHY)
• TABLE 100 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY CANCER 2021-2027 (%) (GEOGRAPHY)
• TABLE 101 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY CANCER 2021-2027 (%) (GEOGRAPHY)
• TABLE 102 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY CARDIOVASCULAR DISEASES 2021-2027 (%) (GEOGRAPHY)
• TABLE 103 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY CARDIOVASCULAR DISEASES 2021-2027 (%) (GEOGRAPHY)
• TABLE 104 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY NERVOUS SYSTEM DISORDERS 2021-2027 (%) (GEOGRAPHY)
• TABLE 105 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY NERVOUS SYSTEM DISORDERS 2021-2027 (%) (GEOGRAPHY)
• TABLE 106 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY INFECTIOUS DISEASES 2021-2027 (%) (GEOGRAPHY)
• TABLE 107 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY INFECTIOUS DISEASES 2021-2027 (%) (GEOGRAPHY)
• TABLE 108 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY MUSCULOSKELETAL DISEASES 2021-2027 (%) (GEOGRAPHY)
• TABLE 109 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY MUSCULOSKELETAL DISEASES 2021-2027 (%) (GEOGRAPHY)
• TABLE 110 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY GASTROENTEROLOGY DISEASES 2021-2027 (%) (GEOGRAPHY)
• TABLE 111 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY GASTROENTEROLOGY DISEASES 2021-2027 (%) (GEOGRAPHY)
• TABLE 112 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY OTHER DISEASES 2021-2027 (%) (GEOGRAPHY)
• TABLE 113 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY OTHER DISEASES 2021-2027 (%) (GEOGRAPHY)
• TABLE 114 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY SMALL & MID-SIZE ENTERPRISES 2021-2027 (%) (GEOGRAPHY)
• TABLE 115 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY SMALL & MID-SIZE ENTERPRISES 2021-2027 (%) (GEOGRAPHY)
• TABLE 116 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY LARGE ENTERPRISES 2021-2027 (%) (GEOGRAPHY)
• TABLE 117 GLOBAL CLINICAL TRIALS OUTSOURCING MARKET BY LARGE ENTERPRISES 2021-2027 (%) (GEOGRAPHY)

The clinical trials outsourcing market is expected to grow at a CAGR of 6.71%during 2022-2027.

The pharma & biotech companies hire other companies to conduct the clinical trials, as the companies do not have the expertise, time, or infrastructure to carry out the clinical trials. Outsourcing clinical trials delivers advantages such as cost efficiency, minimum timeline, and best result delivery. Most clinical trials are outsourced to contract research organizations and third-party vendors.

Clinical trial outsourcing delivers significant advantages in terms of cost. Clinical drug development trials are vital, requiring higher expenditure and high-class infrastructure and expertise. Due to the complexity of clinical trial processes, sponsors constantly face pressure from regulatory agencies, insurers, and the medical community to reduce costs by increasing the size of development projects, their pipelines' pipeline quality and safety of their products, and their compliance with regulatory requirements.

Most Biopharmaceutical companies spend their higher expenditure on research & development activities and clinical trials. In the end, lower chances of success rate impact the company's growth largely; therefore, outsourcing easily reduces this complexity. Remote trials can reduce around 25% to 30% trials cost due to the services associated with patient travel and the number of staff required for monitoring on the site.

Impact of Covid-19 Pandemic

The Covid-19 pandemic gave an absolute massive shift and forced the clinical trial industries to look for outsourcing. Clinical trial complexity is a significant factor that drives clinical trial outsourcing. Robust pipelines and stringent regulations in clinical trials operate the clinical development services.

Virtual Clinical Trials: The Rising Market

Virtual clinical trials are a rapidly increasing trend in biopharma industries. It is one of the new clinical trial models, a highly underutilized method for conducting clinical trials and clinical research. Virtual clinical trials are cost-effective, time-saving, and easier for participants. Virtual collaboration strategies in clinical trials, using clinical trials software allows businesses to work rapidly and more efficiently, eliminates the need for document sharing to additional office locations, and reduces the burden.

KEY INDUSTRY INSIGHTS

• Downscaling the companies, managing the cost of the research, and reducing the expenditure has led to raised clinical trial outsourcing by the biopharmaceutical industry. The three significant factors, globalization, digitalization, and personalized medicines, highly impacted the clinical trials industries. These three major factors have positively influenced the clinical trial outsourcing market growth in recent years.
• Across the world, the rising patient population is one of the major problems for developed countries as their healthcare expenditure is increasing, so there is a demand for advanced treatments which provide value-based solutions to the patients. Biopharmaceutical companies constantly look for new drugs and derived clinical trial activities. Pharma Research and development outsourcing activities are significant in the industry, giving high potential for this market and related activities and triggering the demand for clinical trials outsourcing.
• AI in clinical trials is a revolutionizing technology primarily adopted among large CROs. In recent years AI application was rapidly explored during the COVID-19 pandemic period accelerating the clinical trials for a faster cure for the pandemic.
• The Indian biotech industry alone accounts for 2,700 start-ups, and the estimated number will increase to 10,000 by 2024. Globally, more than 2,093,000 pharma start-ups are running in the market; this rise in smaller companies will demand outsourcing clinical trials.
• Synthetic Data Improving Clinical Development minimizes or replaces the control arm of the clinical trial. It reduces the demand for patient recruitment, saves time and money, and eliminates the ethical issues regarding the placebo.

Usually, the pharma companies do not have access to real-world data. They majorly limit themselves within the clinical trials that they have conducted. This synthetic data, which is from real-world data, will help the companies to understand the real world and help them to find better solutions. Currently, there is an increase in single-arm clinical trials for rare diseases and oncology therapeutic areas. This has made it easy for people to work when comparing treatments. The entry of synthetic and external control arms has changed rapidly and growing significantly by enabling improved access to data, including statistical tool kits from various clinical research fields.

Segmentation by Application

• Cancer
• CVDs
• Infectious Diseases
• Infectious Diseases
• Musculoskeletal Diseases
• Nervous System Disorders
• Other Diseases

Segmentation by Clinical Trial Phase

• Phase I
• Phase II
• Phase III
• Phase IV

Segmentation by End-Users

• Small & Mid-Size Companies
• Large Size Companies

CLINICAL TRIALS OUTSOURCING MARKET TRENDS

• Implementing artificial intelligence (AI) in clinical trials is a revolutionizing technology, primarily adopted among large CROs. In recent years AI application was rapidly explored during the COVID-19 pandemic period accelerating the clinical trials for a faster cure for the pandemic. AI (Artificial Intelligence) helps make every clinical trial stage more efficient with design and patient recruitment and retention, followed by clinical trials outsourcing services by contract research organizations. It also allowed the companies to manage the extensive data without any errors and make decisions accordingly.
• Pharmaceutical and biotech companies are relying on research and development activities to develop new drugs. Rising expenditure on clinical research and development will deliver high market growth opportunities.
• An excellent opportunity for outsourcing clinical trials lies in rare diseases due to the limited patient population and rising prevalence of rare diseases globally. For outsourcing leaders, patient recruitment and retention are easy with the rising prevalence of rare diseases in low-middle companies. These CROs have an excellent partnership with government bodies and large healthcare providers to recruit patients. Most outsourcing companies are based in low-middle-income countries.
• The increasing demand for large molecules and personalized medicines such as cell and gene therapies have also helped drive the CRO outsourcing market consistently.
• An increasing number of small biopharma companies is one of the best clinical trial outsourcing market opportunities. The small and medium-sized biopharma companies account for a higher number of clinical research. Due to lower capital availability, lack of infrastructure, and expertise, small biopharma companies look towards outsourcing clinical trials.

INSIGHTS BY GEOGRAPHY

North America is the leading region in clinical trial outsourcing. But in recent years, clinical trial outsourcing shifting towards the emerging market. Emerging markets such as low-middle-income countries are the best geography for this market due to the high patient population and unaffordable pricing of new treatments or existing treatments in the LMICs.

On the other side, some emerging markets, such as BRICS (Brazil, Russia, India, China, and South Africa), have a better opportunity for clinical trials outsourcing market. These emerging geographies have a high potential for outsourcing trials. High patient pool demography is one of the strong reasons for outsourcing in those countries.

Segmentation by Geography

• APAC
  • China
  • Japan
  • South Korea
  • Australia
  • India
• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
• Latin America
  • Brazil
  • Mexico
• Middle East & Africa
  • Saudi Arabia
  • UAE

Key Vendors:

• Charles River Laboratories
• IQVIA
• ICON plc
• Labcorp Drug Development
• Syneos Health
• Thermo Fischer Scientific
• Wuxi AppTec
• Paraxel

Other Prominent Vendors

• Advanced Clinical
• Bioanalytix
• Curia Global
• CMED
• Cromos Pharma
• Criterium
• KCR SA.
• Medpace
• Medelis
• Oct Group
• Protrials Research
• Prometrika
• Quality Data Services
• QPS
• Sofpromed
• Veristat
• Worldwide Clinical Trials

KEY QUESTIONS ANSWERED

• 1. WHAT IS THE EXPECTED GROWTH OF THE CLINICAL TRIALS OUTSOURCING MARKET IN THE GLOBAL MARKET?
• 2. WHO ARE THE MAJOR PLAYERS IN THE CLINICAL TRIALS OUTSOURCING MARKET?
• 3. WHAT IS THE GROWTH RATE OF THE CLINICAL TRIALS OUTSOURCING MARKET?
• 4. HOW DOES COVID-19 IMPACT THE MARKET GROWTH OF CLINICAL TRIALS OUTSOURCING MARKET SHARE?
• 5. WHAT ARE THE FACTORS DRIVING THE CLINICAL TRIALS OUTSOURCING MARKET GROWTH?

TABLE OF CONTENTS

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

• 4.1 MARKET DEFINITION
  • 4.1.1 INCLUSIONS
  • 4.1.2 EXCLUSIONS
  • 4.1.3 MARKET ESTIMATION CAVEATS
• 4.2 BASE YEAR
• 4.3 SCOPE OF THE STUDY
  • 4.3.1 MARKET SEGMENTATION BY CLINICAL TRIAL PHASE
  • 4.3.2 MARKET SEGMENTATION BY APPLICATION
  • 4.3.3 MARKET SEGMENTATION BY END USER
  • 4.3.4 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

• 5.1 KEY CAVEATS
• 5.2 CURRENCY CONVERSION
• 5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 INTRODUCTION

• 7.1 OVERVIEW

8 PREMIUM INSIGHTS

• 8.1 OVERVIEW
  • 8.1.1 TRENDS IN CLINICAL TRIALS OUTSOURCING

9 MARKET OPPORTUNITIES & TRENDS

• 9.1 RISING DEMAND FOR PATIENT-CENTRIC & DECENTRALIZED CLINICAL TRIALS
• 9.2 REVOLUTIONIZING EFFECTS OF AI ON CLINICAL TRIALS
• 9.3 ENTRY OF START-UPS SPECIALIZING IN DRUG DISCOVERY
• 9.4 INCREASING ADOPTION OF SYNTHETIC CLINICAL TRIALS

10 MARKET GROWTH ENABLERS

• 10.1 SURGE IN DRUG DISCOVERY INITIATIVES AND ASSOCIATED EXPENDITURE
• 10.2 HIGH DEMAND FOR LARGE MOLECULE PRODUCTS & PERSONALIZED MEDICINES
• 10.3 INITIATIVES TO IMPROVE EFFICIENCY IN CLINICAL TRIALS
• 10.4 RISE IN STRATEGIC PARTNERSHIPS AND R&D COLLABORATIONS

11 MARKET RESTRAINTS

• 11.1 GEOGRAPHICAL LOCATIONS AND CRUCIAL REGULATORY ASPECTS FOR CLINICAL TRIALS
• 11.2 LONG TIMELINES AND LACK OF TRANSPARENCY & SPECIFICITY
• 11.3 INCREASING COMPLEXITY OF CLINICAL TRIALS

12 MARKET LANDSCAPE

• 12.1 MARKET OVERVIEW
  • 12.1.1 INSIGHTS BY GEOGRAPHY
  • 12.1.2 INSIGHTS BY CLINICAL TRIALS PHASE
  • 12.1.3 INSIGHTS BY APPLICATION
  • 12.1.4 INSIGHTS BY END USERS
• 12.2 MARKET SIZE & FORECAST
• 12.3 FIVE FORCES ANALYSIS
  • 12.3.1 THREAT OF NEW ENTRANTS
  • 12.3.2 BARGAINING POWER OF SUPPLIERS
  • 12.3.3 BARGAINING POWER OF BUYERS
  • 12.3.4 THREAT OF SUBSTITUTES
  • 12.3.5 COMPETITIVE RIVALRY

13 PHASE

• 13.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 13.1.1 MARKET SIZE & FORECAST
• 13.2 MARKET OVERVIEW
• 13.3 PHASE III
  • 13.3.1 MARKET OVERVIEW
  • 13.3.2 MARKET BY GEOGRAPHY
• 13.4 PHASE II
  • 13.4.1 MARKET OVERVIEW
  • 13.4.2 MARKET SIZE & FORECAST
  • 13.4.3 MARKET BY GEOGRAPHY
• 13.5 PHASE IV
  • 13.5.1 MARKET OVERVIEW
  • 13.5.2 MARKET SIZE & FORECAST
  • 13.5.3 MARKET BY GEOGRAPHY
• 13.6 PHASE I
  • 13.6.1 MARKET OVERVIEW
  • 13.6.2 MARKET SIZE & FORECAST
  • 13.6.3 MARKET BY GEOGRAPHY

14 APPLICATION

• 14.1 MARKET SNAPSHOT & GROWTH ENGINE
• 14.2 MARKET OVERVIEW
• 14.3 CANCER
  • 14.3.1 MARKET OVERVIEW
  • 14.3.2 MARKET SIZE & FORECAST
  • 14.3.3 MARKET BY GEOGRAPHY
• 14.4 CARDIOVASCULAR DISEASES
  • 14.4.1 MARKET OVERVIEW
  • 14.4.2 MARKET SIZE & FORECAST
  • 14.4.3 MARKET BY GEOGRAPHY
• 14.5 NERVOUS SYSTEM DISORDERS
  • 14.5.1 MARKET OVERVIEW
  • 14.5.2 MARKET SIZE & FORECAST
  • 14.5.3 MARKET BY GEOGRAPHY
• 14.6 INFECTIOUS DISEASES
  • 14.6.1 MARKET OVERVIEW
  • 14.6.2 MARKET SIZE & FORECAST
  • 14.6.3 MARKET BY GEOGRAPHY
• 14.7 MUSCULOSKELETAL DISEASES
  • 14.7.1 MARKET OVERVIEW
  • 14.7.2 MARKET SIZE & FORECAST
  • 14.7.3 MARKET BY GEOGRAPHY
• 14.8 GASTROENTEROLOGY DISEASES
  • 14.8.1 MARKET OVERVIEW
  • 14.8.2 MARKET SIZE & FORECAST
  • 14.8.3 MARKET BY GEOGRAPHY
• 14.9 OTHERS
  • 14.9.1 MARKET OVERVIEW
  • 14.9.2 MARKET SIZE & FORECAST
  • 14.9.3 MARKET BY GEOGRAPHY

15 END USER

• 15.1 MARKET SNAPSHOT & GROWTH ENGINE
• 15.2 MARKET OVERVIEW
• 15.3 SMALL & MID-SIZE COMPANIES
  • 15.3.1 MARKET OVERVIEW
  • 15.3.2 MARKET SIZE & FORECAST
  • 15.3.3 MARKET BY GEOGRAPHY
• 15.4 LARGE ENTERPRISES
  • 15.4.1 MARKET OVERVIEW
  • 15.4.2 MARKET SIZE & FORECAST
  • 15.4.3 MARKET BY GEOGRAPHY

16 GEOGRAPHY

• 16.1 MARKET SNAPSHOT & GROWTH ENGINE
• 16.2 GEOGRAPHIC OVERVIEW

17 NORTH AMERICA

• 17.1 MARKET OVERVIEW
• 17.2 MARKET SIZE & FORECAST
• 17.3 PHASE
  • 17.3.1 MARKET SIZE & FORECAST
• 17.4 APPLICATION
  • 17.4.1 MARKET SIZE & FORECAST
• 17.5 END USER
  • 17.5.1 MARKET SIZE & FORECAST
• 17.6 KEY COUNTRIES
  • 17.6.1 US: MARKET SIZE & FORECAST
  • 17.6.2 CANADA: MARKET SIZE & FORECAST

18 EUROPE

• 18.1 MARKET OVERVIEW
• 18.2 MARKET SIZE & FORECAST
• 18.3 PHASE
  • 18.3.1 MARKET SIZE & FORECAST
• 18.4 APPLICATION
  • 18.4.1 MARKET SIZE & FORECAST
• 18.5 END USER
  • 18.5.1 MARKET SIZE & FORECAST
• 18.6 KEY COUNTRIES
  • 18.6.1 GERMANY: MARKET SIZE & FORECAST
  • 18.6.2 UK: MARKET SIZE & FORECAST
  • 18.6.3 FRANCE: MARKET SIZE & FORECAST
  • 18.6.4 SPAIN: MARKET SIZE & FORECAST
  • 18.6.5 ITALY: MARKET SIZE & FORECAST

19 APAC

• 19.1 MARKET OVERVIEW
• 19.2 MARKET SIZE & FORECAST
• 19.3 PHASE
  • 19.3.1 MARKET SIZE & FORECAST
• 19.4 APPLICATION
  • 19.4.1 MARKET SIZE & FORECAST
• 19.5 END USER
  • 19.5.1 MARKET SIZE & FORECAST
• 19.6 KEY COUNTRIES
  • 19.6.1 CHINA: MARKET SIZE & FORECAST
  • 19.6.2 JAPAN: MARKET SIZE & FORECAST
  • 19.6.3 INDIA: MARKET SIZE & FORECAST
  • 19.6.4 AUSTRALIA: MARKET SIZE & FORECAST
  • 19.6.5 SOUTH KOREA: MARKET SIZE & FORECAST

20 LATIN AMERICA

• 20.1 MARKET OVERVIEW
• 20.2 MARKET SIZE & FORECAST
• 20.3 PHASE
  • 20.3.1 MARKET SIZE & FORECAST
• 20.4 APPLICATION
  • 20.4.1 MARKET SIZE & FORECAST
• 20.5 END USER
  • 20.5.1 MARKET SIZE & FORECAST
• 20.6 KEY COUNTRIES
  • 20.6.1 BRAZIL: MARKET SIZE & FORECAST
  • 20.6.2 MEXICO: MARKET SIZE & FORECAST

21 MIDDLE EAST & AFRICA

• 21.1 MARKET OVERVIEW
• 21.2 MARKET SIZE & FORECAST
• 21.3 PHASE
  • 21.3.1 MARKET SIZE & FORECAST
• 21.4 APPLICATION
  • 21.4.1 MARKET SIZE & FORECAST
• 21.5 END USER
  • 21.5.1 MARKET SIZE & FORECAST
• 21.6 KEY COUNTRIES
  • 21.6.1 TURKEY: MARKET SIZE & FORECAST
  • 21.6.2 EGYPT: MARKET SIZE & FORECAST
  • 21.6.3 SOUTH AFRICA: MARKET SIZE & FORECAST
  • 21.6.4 SAUDI ARABIA: MARKET SIZE & FORECAST

22 COMPETITIVE LANDSCAPE

• 22.1 COMPETITION OVERVIEW
• 22.2 MARKET SHARE ANALYSIS
  • 22.2.1 CHARLES RIVER LABORATORIES
  • 22.2.2 IQVIA
  • 22.2.3 ICON PLC
  • 22.2.4 LABCORP DRUG DEVELOPMENT
  • 22.2.5 SYNEOS HEALTH
  • 22.2.6 THERMO FISCHER SCIENTIFIC
  • 22.2.7 WUXI APPTEC
  • 22.2.8 PARAXEL

23 KEY COMPANY PROFILES

• 23.1 CHARLES RIVER LABORATORIES
  • 23.1.1 BUSINESS OVERVIEW
  • 23.1.2 PRODUCT OFFERINGS
  • 23.1.3 KEY STRATEGIES
  • 23.1.4 KEY STRENGTHS
  • 23.1.5 KEY OPPORTUNITIES
• 23.2 IQVIA
  • 23.2.1 BUSINESS OVERVIEW
  • 23.2.2 PRODUCT OFFERINGS
  • 23.2.3 KEY STRATEGIES
  • 23.2.4 KEY STRENGTHS
  • 23.2.5 KEY OPPORTUNITIES
• 23.3 ICON PLC
  • 23.3.1 BUSINESS OVERVIEW
  • 23.3.2 PRODUCT OFFERINGS
  • 23.3.3 KEY STRATEGIES
  • 23.3.4 KEY STRENGTHS
  • 23.3.5 KEY OPPORTUNITIES
• 23.4 LABCORP DRUG DEVELOPMENT
  • 23.4.1 BUSINESS OVERVIEW
  • 23.4.2 SERVICE OFFERINGS
  • 23.4.3 KEY STRATEGIES
  • 23.4.4 KEY STRENGTHS
  • 23.4.5 KEY OPPORTUNITIES
• 23.5 SYNEOS HEALTH
  • 23.5.1 BUSINESS OVERVIEW
  • 23.5.2 SERVICE OFFERINGS
  • 23.5.3 KEY STRATEGIES
  • 23.5.4 KEY STRENGTHS
  • 23.5.5 KEY OPPORTUNITIES
• 23.6 THERMO FISHER SCIENTIFIC
  • 23.6.1 BUSINESS OVERVIEW
  • 23.6.2 SERVICE OFFERINGS
  • 23.6.3 KEY STRATEGIES
  • 23.6.4 KEY STRENGTHS
  • 23.6.5 KEY OPPORTUNITIES
• 23.7 WUXI APPTEC
  • 23.7.1 BUSINESS OVERVIEW
  • 23.7.2 SERVICE OFFERINGS
  • 23.7.3 KEY STRATEGIES
  • 23.7.4 KEY STRENGTHS
  • 23.7.5 KEY OPPORTUNITIES
• 23.8 PARAXEL
  • 23.8.1 BUSINESS OVERVIEW
  • 23.8.2 SERVICE OFFERINGS
  • 23.8.3 KEY STRATEGIES
  • 23.8.4 KEY STRENGTHS
  • 23.8.5 KEY OPPORTUNITIES

24 OTHER PROMINENT VENDORS

• 24.1 ADVANCED CLINICAL
  • 24.1.1 BUSINESS OVERVIEW
  • 24.1.2 SERVICE OFFERINGS
• 24.2 BIOANALYTIX
  • 24.2.1 BUSINESS OVERVIEW
  • 24.2.2 SERVICE OFFERINGS
• 24.3 CURIA GLOBAL
  • 24.3.1 BUSINESS OVERVIEW
  • 24.3.2 SERVICE OFFERINGS
• 24.4 CMED
  • 24.4.1 BUSINESS OVERVIEW
  • 24.4.2 SERVICE OFFERINGS
• 24.5 CROMOS PHARMA
  • 24.5.1 BUSINESS OVERVIEW
  • 24.5.2 SERVICE OFFERINGS
• 24.6 CRITERIUM
  • 24.6.1 BUSINESS OVERVIEW
  • 24.6.2 SERVICE OFFERINGS
• 24.7 KCR S.A.
  • 24.7.1 BUSINESS OVERVIEW
  • 24.7.2 SERVICE OFFERINGS
• 24.8 MEDPACE
  • 24.8.1 BUSINESS OVERVIEW
  • 24.8.2 SERVICE OFFERINGS
• 24.9 MEDELIS
  • 24.9.1 BUSINESS OVERVIEW
  • 24.9.2 SERVICE OFFERINGS
• 24.10 OCT GROUP
  • 24.10.1 BUSINESS OVERVIEW
  • 24.10.2 SERVICE OFFERINGS
• 24.11 PROTRIALS RESEARCH
  • 24.11.1 BUSINESS OVERVIEW
  • 24.11.2 SERVICE OFFERINGS
• 24.12 PROMETRIKA
  • 24.12.1 BUSINESS OVERVIEW
  • 24.12.2 SERVICE OFFERINGS
• 24.13 QUALITY DATA SERVICES
  • 24.13.1 BUSINESS OVERVIEW
  • 24.13.2 SERVICE OFFERINGS
• 24.14 QPS
  • 24.14.1 BUSINESS OVERVIEW
  • 24.14.2 SERVICE OFFERINGS
• 24.15 SOFPROMED
  • 24.15.1 BUSINESS OVERVIEW
  • 24.15.2 SERVICE OFFERINGS
• 24.16 VERISTAT
  • 24.16.1 BUSINESS OVERVIEW
  • 24.16.2 SERVICE OFFERINGS
• 24.17 WORLDWIDE CLINICAL TRIALS
  • 24.17.1 BUSINESS OVERVIEW
  • 24.17.2 SERVICE OFFERINGS

25 REPORT SUMMARY

• 25.1 KEY TAKEAWAYS
• 25.2 STRATEGIC RECOMMENDATIONS

26 QUANTITATIVE SUMMARY

• 26.1 MARKET BY GEOGRAPHY
• 26.2 MARKET BY PHASE
• 26.3 MARKET BY APPLICATION
• 26.4 MARKET BY END USER
• 26.5 MARKET BY PHASE
  • 26.5.1 PHASE III: GEOGRAPHY DISTRIBUTION
  • 26.5.2 PHASE II: GEOGRAPHY DISTRIBUTION
  • 26.5.3 PHASE IV: GEOGRAPHY DISTRIBUTION
  • 26.5.4 PHASE I: GEOGRAPHY DISTRIBUTION
• 26.6 MARKET BY APPLICATION
  • 26.6.1 CANCER: GEOGRAPHY DISTRIBUTION
  • 26.6.2 CARDIOVASCULAR DISEASES (CVDS): GEOGRAPHY DISTRIBUTION
  • 26.6.3 NERVOUS SYSTEM DISORDERS: GEOGRAPHY DISTRIBUTION
  • 26.6.4 INFECTIOUS DISEASES: GEOGRAPHY DISTRIBUTION
  • 26.6.5 MUSCULOSKELETAL DISEASES: GEOGRAPHY DISTRIBUTION
  • 26.6.6 GASTROENTEROLOGY DISEASES: GEOGRAPHY DISTRIBUTION
  • 26.6.7 OTHER DISEASES: GEOGRAPHY DISTRIBUTION
• 26.7 MARKET BY END USER
  • 26.7.1 SMALL & MID-SIZE COMPANIES: GEOGRAPHY DISTRIBUTION
  • 26.7.2 LARGE ENTERPRISES: GEOGRAPHY DISTRIBUTION

27 APPENDIX

• 27.1 ABBREVIATIONS